GlassScriptPhysician profile
Carlos E Coelho
NPI 1184705196
$9,468.45
in general payments reported to CMS, 2019-2025
32 companies · $1,671 in 2025
The $1,671 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,225 · 2020: $995 · 2021: $1,389 · 2022: $1,705 · 2023: $1,280 · 2024: $1,204 · 2025: $1,671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,154.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,092.44 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,279.94 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Insulet Corporation | $1,163.86 | 2019-2025 | Omnipod, Omnipod |
| Sanofi-Aventis U.S. LLC | $700.19 | 2019-2025 | |
| Abbott Laboratories | $634.23 | 2019-2025 | Freestyle Libre 3 |
| Amgen INC. | $477.80 | 2019-2025 | Tepezza, Evenity, Prolia |
| Abbvie INC. | $437.79 | 2019-2025 | Synthroid |
| Mannkind Corporation | $377.75 | 2020-2025 | Afrezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $261.36 | 2019-2025 | Jardiance |
| Xeris Pharmaceuticals, INC. | $255.29 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Tandem Diabetes Care, INC. | $187.02 | 2019-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Dexcom, INC. | $169.32 | 2020-2025 | Dexcom G6 Transmitter |
| Cequr Corporation | $151.90 | 2022-2024 | Cequr Simplicity |
| Medtronic Minimed, INC. | $151.72 | 2019-2020 | |
| Radius Health, INC. | $147.21 | 2019-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sequel Med Tech, LLC | $141.50 | 2025 | Twiist |
| Corcept Therapeutics | $124.93 | 2024-2025 | Korlym |
| Medtronic, INC. | $109.35 | 2021-2025 | Minimed 780g |
| Shire North American Group INC | $91.72 | 2019 | |
| Amneal Pharmaceuticals LLC | $84.99 | 2019-2022 | |
| Ibsa Pharma INC. | $82.72 | 2022-2025 | Licart, Tirosint, Flector |
| Nevro Corp. | $71.89 | 2022-2023 | Senza |
| Beta Bionics, INC. | $70.81 | 2024 | Ilet Bionic Pancreas |
| Amarin Pharma, INC. | $34.15 | 2019 | |
| Novartis Pharmaceuticals Corporation | $28.41 | 2024 | |
| Madrigal Pharmaceuticals | $27.14 | 2025 | Rezdiffra |
| Glaxosmithkline, LLC. | $23.07 | 2025 | Shingrix, Arexvy |
| Alfasigma USA, INC. | $20.14 | 2021 | |
| Rhythm Pharmaceuticals, INC. | $17.99 | 2025 | Imcivree |
| Esperion Therapeutics, INC. | $17.31 | 2025 | Nexletol |
| Merck Sharp & Dohme LLC | $17.26 | 2019 | |
| Recordati_rare_diseases_inc. | $17.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Coelho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.